Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-risk Neuroblastoma: Children’s Oncology Group Study ANBL0032

PURPOSE: Previously our randomized Phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 monoclonal antibody, granulocyte macrophage-colony stimulating factor (GM-CSF), and interleukin-2 (IL2) improved survival for children with high-risk neuroblastoma that had r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Yu, Alice L., Gilman, Andrew L., Ozkaynak, M. Fevzi, Naranjo, Arlene, Diccianni, Mitchell B., Gan, Jacek, Hank, Jacquelyn A., Batova, Ayse, London, Wendy B., Tenney, Sheena C., Smith, Malcolm, Shulkin, Barry L., Parisi, Marguerite, Matthay, Katherine K., Cohn, Susan L., Maris, John M., Bagatell, Rochelle, Park, Julie R., Sondel, Paul M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8046731/
https://ncbi.nlm.nih.gov/pubmed/33504555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3909
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados